Clinical Trial Update: Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating three dosing regimens of CP-690,550 (tofacitinib) versus placebo for efficacy and safety in adults with moderate-to-severe chronic pl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2012-12-19